PL3891138T3 - Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu - Google Patents
Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniuInfo
- Publication number
- PL3891138T3 PL3891138T3 PL21707628T PL21707628T PL3891138T3 PL 3891138 T3 PL3891138 T3 PL 3891138T3 PL 21707628 T PL21707628 T PL 21707628T PL 21707628 T PL21707628 T PL 21707628T PL 3891138 T3 PL3891138 T3 PL 3891138T3
- Authority
- PL
- Poland
- Prior art keywords
- targeted delivery
- activation protein
- fibroblast activation
- delivery applications
- protein ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157036 | 2020-02-12 | ||
| EP20172953 | 2020-05-05 | ||
| EP20202856 | 2020-10-20 | ||
| PCT/EP2021/053494 WO2021160825A1 (en) | 2020-02-12 | 2021-02-12 | Fibroblast activation protein ligands for targeted delivery applications |
| EP21707628.0A EP3891138B1 (en) | 2020-02-12 | 2021-02-12 | Fibroblast activation protein ligands for targeted delivery applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3891138T3 true PL3891138T3 (pl) | 2022-05-02 |
Family
ID=74701462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21707628T PL3891138T3 (pl) | 2020-02-12 | 2021-02-12 | Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP3891138B1 (pl) |
| DK (1) | DK3891138T3 (pl) |
| ES (1) | ES2910941T3 (pl) |
| HU (1) | HUE058835T2 (pl) |
| PL (1) | PL3891138T3 (pl) |
| WO (1) | WO2021160825A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021016392A1 (en) * | 2019-07-22 | 2021-01-28 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
| EP4043452A1 (en) * | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| CN113880810B (zh) * | 2021-09-24 | 2023-02-28 | 厦门大学 | 一种核素标记的配合物及其制备方法和应用 |
| CN113880811B (zh) * | 2021-09-29 | 2022-09-02 | 厦门大学附属第一医院 | Fapi二聚体化合物、基于fapi二聚体的肿瘤诊断pet显像剂及其制备方法和应用 |
| MX2024004077A (es) * | 2021-10-04 | 2024-04-18 | Philochem Ag | Ligandos de proteina de activacion de fibroblastos radioetiquetados. |
| DE102021133942A1 (de) * | 2021-12-20 | 2023-06-22 | Atoms for Cure GmbH | FAP-adressierendes Pharmazeutikum für die Therapie und Diagnose von Krebserkrankungen |
| CN116554146A (zh) * | 2022-01-29 | 2023-08-08 | 中国科学院生物物理研究所 | 一种FAP-α特异性放射性药物及其应用 |
| US20250177582A1 (en) | 2022-01-30 | 2025-06-05 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
| CN115304582B (zh) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-α特异性肿瘤诊断显像剂 |
| WO2024022332A1 (en) * | 2022-07-26 | 2024-02-01 | Shanghai Sinotau Biotech. Co., Ltd | Fap inhibitors |
| CN119816493A (zh) * | 2022-09-06 | 2025-04-11 | 菲罗化学股份公司 | 用于靶向递送应用的多价成纤维细胞激活蛋白配体 |
| EP4342890A1 (en) | 2022-09-21 | 2024-03-27 | Erasmus University Rotterdam Medical Center | Platform and scaffold for fap targeting agents |
| AU2023347470A1 (en) | 2022-09-23 | 2025-04-10 | Nuclidium Ag | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
| TW202426433A (zh) * | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途 |
| CN117883585A (zh) * | 2022-10-14 | 2024-04-16 | 无锡诺宇医药科技有限公司 | 靶向成纤维细胞活化蛋白的药物及其应用 |
| WO2024197111A2 (en) * | 2023-03-22 | 2024-09-26 | Regents Of The University Of Michigan | Radiolabeled fibroblast activation protein inhibitors and methods of making same |
| KR102924988B1 (ko) * | 2023-07-04 | 2026-02-06 | 이화여자대학교 산학협력단 | 화합물, 이를 포함한 조성물 및 이를 이용한 광역학 진단 또는 치료 방법 |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
| WO2025063849A2 (en) | 2023-09-21 | 2025-03-27 | Erasmus University Medical Center Rotterdam | Dimeric fap targeting agents |
| WO2025125335A1 (en) * | 2023-12-13 | 2025-06-19 | Radiovaxx Gmbh | Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group |
| WO2026010658A2 (en) * | 2024-03-22 | 2026-01-08 | Nuclidium Ag | Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof |
| WO2025250709A1 (en) * | 2024-05-28 | 2025-12-04 | Actithera, Inc. | Bifunctional compounds for cancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1729774A4 (en) | 2004-03-09 | 2009-05-06 | Nat Health Research Institutes | PYRROLIDINE CONNECTIONS |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| JP2021506972A (ja) | 2017-12-15 | 2021-02-22 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| WO2019154859A1 (en) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| SG11202007180QA (en) | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
-
2021
- 2021-02-12 EP EP21707628.0A patent/EP3891138B1/en active Active
- 2021-02-12 ES ES21707628T patent/ES2910941T3/es active Active
- 2021-02-12 HU HUE21707628A patent/HUE058835T2/hu unknown
- 2021-02-12 EP EP22150696.7A patent/EP4019507A1/en active Pending
- 2021-02-12 DK DK21707628.0T patent/DK3891138T3/da active
- 2021-02-12 PL PL21707628T patent/PL3891138T3/pl unknown
- 2021-02-12 WO PCT/EP2021/053494 patent/WO2021160825A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK3891138T3 (da) | 2022-04-04 |
| HUE058835T2 (hu) | 2022-09-28 |
| ES2910941T3 (es) | 2022-05-17 |
| EP3891138A1 (en) | 2021-10-13 |
| EP3891138B1 (en) | 2022-01-12 |
| WO2021160825A1 (en) | 2021-08-19 |
| EP4019507A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3891138T3 (pl) | Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu | |
| IL292113A (en) | Bicyclic drug ligand conjugates | |
| SI3997103T1 (sl) | Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh | |
| IL311694A (en) | A radiolabeled fibroblast activation protein ligand | |
| IL289673A (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| IL276784A (en) | Drug delivery systems | |
| IL284434A (en) | Fibroblast activation protein inhibitors | |
| CA3266566A1 (en) | MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | |
| EP3712179A4 (en) | BINDING UNIT DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN ALPHA AND APPLICATION OF IT | |
| GB202004701D0 (en) | Delivery system | |
| EP4340619A4 (en) | MODIFIED ANTIMICROBIAL PEPTIDES | |
| GB202008130D0 (en) | Delivery system | |
| HK40102910A (en) | Bivalent fibroblast activation protein ligands for targeted delivery applications | |
| EP3515466A4 (en) | OPTIMIZED SYNTHETIC INMUNOGENOUS CONSENSUS COMPOSITIONS AGAINST FIBROBLAST ACTIVATION PROTEIN | |
| GB202008120D0 (en) | Delivery system | |
| GB202004730D0 (en) | Delivery system | |
| GB202004707D0 (en) | Delivery system | |
| WO2024049961A9 (en) | Treatment for ovarian cancer with oligonucleotides targeting fibroblast activation protein alpha | |
| PT3997103T (pt) | Compostos que compreendem um ligando da proteína de ativação de fibroblastos e sua utilização | |
| GB202110820D0 (en) | Targeted protein degradation | |
| GB201914875D0 (en) | Bicyclic peptide ligand drug conjugates | |
| GB201914196D0 (en) | Bicyclic peptide ligand Drug conjugates | |
| GB201914194D0 (en) | Bicyclic peptide ligand drug conjugates | |
| GB202114282D0 (en) | Bicyclic peptide ligand drug conjugates | |
| GB202114279D0 (en) | Bicyclic peptide ligand drug conjugates |